BCNU
Information
- Drug Name
- BCNU
- Description
- Entry(CIViC)
CIViC
[No Data.]
Annotation
| Description | Associated Genes | Associated Variants | Sensitivity | Supported | Source | Links |
|---|---|---|---|---|---|---|
| BCNU (1,3-bis(2-chloroethyl)-1-nitrosourea) is a c... | MGMT | MGMT UNDEREXPRESSION | Sensitivity | true | MMMP | detail |
| p73 is a p53 homologue; p73 gene silencing is asso... | ARHGAP24 | ARHGAP24 METHYLATION | Sensitivity | true | MMMP | detail |
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT01011920 | Completed | Phase 2 | Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma | November 2009 | March 2017 |
| NCT00083551 | Completed | Phase 3 | UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy | August 1998 | August 2014 |
| NCT00137995 | Completed | Phase 3 | R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma | June 2003 | October 2008 |
| NCT00005613 | Completed | Phase 2 | Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease | March 1996 | June 2010 |
| NCT00350181 | Completed | Phase 2 | Sirolimus & Mycophenolate Mofetil as GVHD Prophylaxis in Myeloablative, Matched Related Donor HCT | August 2006 | April 2010 |
| NCT00477035 | Completed | Phase 1 | Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies | May 2006 | March 2011 |
| NCT01702961 | Completed | N/A | Rituxan + BEAM and Auto Stem Cell Transplant for High Risk Lymphoma or Hodgkin's Disease | June 2002 | January 2017 |
| NCT01538472 | Completed | Phase 1/Phase 2 | Y Zevalin and BEAM in Autologous Stem Cell Transplantation (ASCT) for Lymphoma | September 2003 | November 2011 |
| NCT01141712 | Completed | Phase 2 | Autologous Transplant in HIV Patients (BMT CTN 0803) | April 2010 | June 2016 |
| NCT00536978 | Completed | Phase 2 | Natural Killer (NK) Cell Adback After Allogeneic Stem Cell Transplant With Campath-IH Plus Chemorx for Patients With Lymphoid Malignancies | September 2007 | November 2010 |
| NCT04150042 | Recruiting | Phase 1 | SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients' Own Stem Cells | January 13, 2021 | December 2025 |
| NCT03125642 | Recruiting | Phase 2 | Auto Stem Cell Transplant for Lymphoma Patients | April 20, 2017 | April 30, 2026 |
| NCT00481832 | Terminated | Phase 2 | Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma | January 2007 | March 30, 2017 |
| NCT03591861 | Terminated | N/A | Therapeutic Targeting of Sex Differences in Pediatric Brain Tumor Glycolysis | May 1, 2019 | November 1, 2022 |
| NCT00505921 | Terminated | Phase 2 | Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma | March 2003 | November 2009 |
| NCT00499018 | Unknown status | Phase 3 | Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma | January 2006 | September 2013 |
| NCT00209222 | Unknown status | Phase 3 | Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL | July 2004 | December 2014 |